

Review

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

Alice Indini ¹, Fausto Petrelli ², Gianluca Tomasello ³, Erika Rijavec ¹, Antonio Facciorusso ⁴, Francesco Grossi ¹ and Michele Ghidini ^{1,*}

¹ Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; alice.indini@gmail.com (A.I.); erika.rijavec@policlinico.mi.it (E.R.); francesco.grossi@policlinico.mi.it (F.G.)

² Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio (BG), Italy; faupe@libero.it

³ Oncology Unit, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20121 Milan, Italy; gianluca.tomasello@ospedaleniguarda.it

⁴ Gastroenterology Unit, Università Degli Studi di Foggia, 71122 Foggia, Italy; antonio.facciorusso@virgilio.it

* Correspondence: Michele.ghidini@policlinico.mi.it; Tel.: +39-02-5503-2660; Fax: +39-02-5503-2659

Received: 29 March 2020; Accepted: 14 April 2020; Published: 18 April 2020



Abstract: We performed a systematic review and meta-analysis to evaluate the role of gastric acid suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy. We identified all research evaluating the effect of GAS (gastric acid suppressants) use on patients receiving oral chemotherapy or TKIs for solid tumors. The pooled hazard ratios (HRs) and 95% confidence interval (95%CI) for overall survival (OS) and progression-free survival (PFS) were calculated with a fixed-effects or a random effects model. The study population included $n = 16$ retrospective studies and 372,418 patients. The series concerned gastrointestinal tract tumors ($n = 5$ studies), renal cell carcinomas (RCC, $n = 3$ studies), non-small cell lung cancers (NSCLC, $n = 5$ studies), and soft tissue sarcomas or mixed histologies solid tumors in $n = 3$ studies. The pooled HRs for OS and PFS were 1.31 (95%CI: 1.20–1.43; $p < 0.01$) and 1.3 (95%CI 1.07–1.57; $p < 0.01$) for GAS and no GAS users, respectively. Only studies of EGFR (epidermal growth factor receptor) mutated NSCLC patients receiving TKIs and those with colorectal cancer receiving oral chemotherapy showed a significant correlation between GAS and poor survival. Our study supports the evidence of a possible negative impact of concomitant GAS therapy on survival outcomes of patients receiving oral anti-cancer drugs.

Keywords: gastric acid suppressant; chemotherapy; tyrosine kinase inhibitors; proton pump inhibitors

1. Introduction

Oral chemotherapy has historically been part of therapeutic regimens for the treatment of cancer [1–3]. Over the last years, new oral anti-cancer agents acting as multi-tyrosine kinase inhibitors (TKIs) have dramatically changed patient prognosis and thereby have become standard treatments for several types of tumors [4–9]. TKIs targeting the epidermal growth factor receptor (EGFR) (e.g., gefitinib, erlotinib, afatinib, osimertinib) are currently approved for treatment of EGFR mutant non-small cell lung carcinoma (NSCLC), and multi-targeted TKIs (e.g., sunitinib, axitinib, sorafenib, pazopanib) for the treatment of renal cell carcinoma (RCC). Moreover, several new TKIs are currently being tested in clinical trials in several types of solid tumors. The use of oral drugs has a positive impact on patient quality of life for the convenience of self-administration; however, there is a significant risk of drug–drug interactions. The diffusion of these drugs often parallels that of gastric acid suppressants (GAS), such as proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2RA). GAS commonly represent part of the complex drug regimen of an average oncologic patient, with an

estimated rate of 50% inappropriate PPIs prescriptions, both in hospital and ambulatory settings [10]. Because of the oral administration and pH-dependent solubility of chemotherapy and TKIs, concerns have been raised over the possible effect of co-administering drugs which raise gastric pH] [11,12]. Chronic acid suppression can reduce the effectiveness of drugs that require an acidic pH for their absorption [13]. Retrospective data suggest that TKI plasma concentration is decreased in patients receiving concomitant GAS therapy with subsequently poorer oncologic outcomes [14,15], however pooled analyses of patients enrolled in clinical trials have shown inconsistent results [16,17].

The aim of our meta-analysis is to define whether concomitant use of GAS therapy (either PPI or H2RA) in patients receiving treatment with oral anti-cancer agents (i.e., chemotherapy or TKIs) is associated with survival outcomes.

2. Results

A total of 353 potentially eligible records were identified in the electronic databases. After exclusion of $n = 337$ not pertinent papers, $n = 16$ were selected for inclusion in quantitative analysis ($n = 372,418$ patients included, with 12% of patients receiving concomitant GAS therapy) [16–31]. The search results and characteristics of the included studies are presented in Figure 1 and Tables 1 and 2.




Figure 1. Flow diagram of included studies.

Table 1. Main characteristics of the included studies.

Author	Principal Institution(s) Involved	Study Design	Study Period	Number of Patients	Patients' Disease Characteristics	Oral Anti-cancer Drug	Type of GAS
Ha, 2014 [23]	Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada	retrospective	2006–2013	383	mRCC	Sunitinib	PPI
Sun, 2016 [27]	Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada	retrospective	2008–2012	298	Early stage CRC	Capecitabine	PPI
Chu, 2015 [19]	Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada	retrospective	2007–2012	507	EGFR mutant advanced NSCLC	Erlotinib	PPI, H2RA
Zenke, 2016 [30]	Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan	retrospective	2008–2011	130	EGFR mutant advanced NSCLC	Gefitinib Erlotinib	PPI, H2RA
Kumarakulasinghe, 2016 [24]	Department of Haematology-Oncology, National University Cancer Institute, Singapore	retrospective	2008–2013	157	EGFR mutant advanced NSCLC	Gefitinib Erlotinib	PPI, H2RA
Chen, 2016 [18]	Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan	retrospective	2010–2013	269	EGFR mutant advanced NSCLC	EGFR TKIs NOS	PPI
Graham, 2016 [21]	Department of Oncology, Cancer Centre of Southeastern Ontario, Queen's University, Kingston	retrospective	2005–2011	117	CRC	NA	PPI
Chu, 2017 [20]	Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada	retrospective analysis (phase III trial)	2008–2012	545	GEJC	Capecitabine	PPI
Zhang, 2017 [31]	Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, China	retrospective	2008–2016	125	CRC	Capecitabine	PPI
Lalani, 2017 [16]	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA	pooled analysis (phase II/III studies)	2003–2013	2188	mRCC	Sunitinib Axitinib Sorafenib	PPI
McAlister, 2018 [25]	Vanderbilt-Ingram Cancer Center, Nashville, USA	retrospective	2010–2015	90	mRCC	Pazopanib	PPI, H2RA

Table 1. Cont.

Author	Principal Institution(s) Involved	Study Design	Study Period	Number of Patients	Patients' Disease Characteristics	Oral Anti-cancer Drug	Type of GAS
Tvingsholm, 2018 [28]	Danish Cancer Society Research Center, Copenhagen, Denmark (Danish Cancer Registry)	retrospective	1995–2011	353,071	Solid Tumors (Danish Cancer Registry)	NA	PPI
Wong, 2019 [29]	Cross Cancer Institute, Department of Oncology, Edmonton, Alberta, Canada	retrospective	2004–2013	389	stage II–III CRC	Capecitabine	PPI
Fang, 2019 [21]	Chang Gung Memorial Hospital, Chiayi Branch, Puzi City, Chiayi County, Taiwan	retrospective	1997–2013	1278	EGFR mutant advanced NSCLC	Gefitinib	PPI
Mir, 2019 [17]	Gustave Roussy, Sarcoma Group, Villejuif, France	retrospective	2005–2007 2008–2010	333	STS	Pazopanib	PPI, H2RA
Sharma, 2019 [26]	The University of Mississippi, Oxford, Mississippi, USA (SEER Database)	retrospective	2007–2012	12,538	Solid Tumors (SEER Database)	TKIs	PPI

Legend: CRC, colorectal cancer; GEJC, gastro-esophageal junction cancer; EGFR, epidermal growth factor receptor; GAS, gastric acid suppressants; H2RA, histamine-2 receptor antagonists; NA, not applicable; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PPI, proton-pump inhibitors; mRCC, metastatic renal cell carcinoma; SEER, Surveillance, Epidemiology, and End Results; STS, soft-tissue sarcoma; TKI, tyrosine kinase inhibitors; USA, United States of America.

Table 2. Response and survival outcomes in the analyzed studies.

Authors, Year	Median Follow-Up, Months	Criteria for Overlapping between GAS and Anti-cancer Treatment (Time Overlapping %)	Therapeutic Approach, n (%)	ORR	OS HR (95% CI) *	PFS HR (95% CI) *	Type of Analysis	Quality NOS Score
Ha, 2014 [23]	NA	100	GAS: 45 (20%) No GAS: 186 (80%)	NA NA	1.43 (0.95–2.15)	1.36 (0.92–2.01)	UVA	5
Sun, 2016 [27]	NA	Any PPI prescription	GAS: 77 (26%) No GAS: 202 (74%)	NA NA	0.94 (0.49–1.78)	0.61 (0.34–1.08)	MVA	5
Chu, 2015 [19]	NA	≥20	GAS: 124 (25%) No GAS: 383 (75%)	5.6% 18.5%	1.37 (1.11–1.69)	1.83 (1.48–2.25)	MVA	6
Zenke, 2016 [30]	36 (10.1–85.2)	PPI/H2RA sequentially or concurrently to anti-EGFR	GAS: 47 (36%) No GAS: 83 (64%)	64% 63%	1.41 (0.83–2.35)	1.15 (0.73–1.79)	MVA	7

Table 2. Cont.

Authors, Year	Median Follow-Up, Months	Criteria for Overlapping between GAS and Anti-cancer Treatment (Time Overlapping %)	Therapeutic Approach, n (%)	ORR	OS HR (95% CI) *	PFS HR (95% CI) *	Type of Analysis	Quality NOS Score																																																																																																																		
Kumarakulasinghe, 2016 [24]	50	≥30	GAS: 55 (35%)	NA	1.37 (0.89–2.12)	1.47 (0.92–2.35)	MVA	7																																																																																																																		
			No GAS: 102 (65%)	NA					Chen, 2016 [18]	24.5	≥30	GAS: 57 (21%)	NA	2.27 (1.26–4.11)	2.00 (0.96–4.17)	MVA	6	No GAS: 212 (79%)	NA	Graham, 2016 [21]	NA	NA	GAS: 117 (9%)	NA	1.34 (1.01–1.79)	NA	MVA	7	No GAS: 1187 (91%)	NA	Chu, 2017 [20]	NA	≥20	GAS: 119 (44%)	36%	1.41 (1.11–1.71)	1.68 (1.42–1.94)	MVA	5	No GAS: 155 (56%)	42%	Zhang, 2017 [31]	66	≥200 mg PPI	GAS: 29 (23%)	52.2%	0.30 (0.09–0.99)	0.37 (0.11–1.23) *	UVA *, MVA	7	No GAS: 96 (77%)	36.5%	Lalani, 2017 [16]	NA	≥1 dose PPI	GAS: 120 (5%)	23.3%	1.05 (0.77–1.44)	1.02 (0.79–1.30)	MVA	5	No GAS: 2068(95%)	27.4%	McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5	No GAS: 24 (27%)	NA	Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)
Chen, 2016 [18]	24.5	≥30	GAS: 57 (21%)	NA	2.27 (1.26–4.11)	2.00 (0.96–4.17)	MVA	6																																																																																																																		
			No GAS: 212 (79%)	NA					Graham, 2016 [21]	NA	NA	GAS: 117 (9%)	NA	1.34 (1.01–1.79)	NA	MVA	7	No GAS: 1187 (91%)	NA	Chu, 2017 [20]	NA	≥20	GAS: 119 (44%)	36%	1.41 (1.11–1.71)	1.68 (1.42–1.94)	MVA	5	No GAS: 155 (56%)	42%	Zhang, 2017 [31]	66	≥200 mg PPI	GAS: 29 (23%)	52.2%	0.30 (0.09–0.99)	0.37 (0.11–1.23) *	UVA *, MVA	7	No GAS: 96 (77%)	36.5%	Lalani, 2017 [16]	NA	≥1 dose PPI	GAS: 120 (5%)	23.3%	1.05 (0.77–1.44)	1.02 (0.79–1.30)	MVA	5	No GAS: 2068(95%)	27.4%	McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5	No GAS: 24 (27%)	NA	Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA				
Graham, 2016 [21]	NA	NA	GAS: 117 (9%)	NA	1.34 (1.01–1.79)	NA	MVA	7																																																																																																																		
			No GAS: 1187 (91%)	NA					Chu, 2017 [20]	NA	≥20	GAS: 119 (44%)	36%	1.41 (1.11–1.71)	1.68 (1.42–1.94)	MVA	5	No GAS: 155 (56%)	42%	Zhang, 2017 [31]	66	≥200 mg PPI	GAS: 29 (23%)	52.2%	0.30 (0.09–0.99)	0.37 (0.11–1.23) *	UVA *, MVA	7	No GAS: 96 (77%)	36.5%	Lalani, 2017 [16]	NA	≥1 dose PPI	GAS: 120 (5%)	23.3%	1.05 (0.77–1.44)	1.02 (0.79–1.30)	MVA	5	No GAS: 2068(95%)	27.4%	McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5	No GAS: 24 (27%)	NA	Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA															
Chu, 2017 [20]	NA	≥20	GAS: 119 (44%)	36%	1.41 (1.11–1.71)	1.68 (1.42–1.94)	MVA	5																																																																																																																		
			No GAS: 155 (56%)	42%					Zhang, 2017 [31]	66	≥200 mg PPI	GAS: 29 (23%)	52.2%	0.30 (0.09–0.99)	0.37 (0.11–1.23) *	UVA *, MVA	7	No GAS: 96 (77%)	36.5%	Lalani, 2017 [16]	NA	≥1 dose PPI	GAS: 120 (5%)	23.3%	1.05 (0.77–1.44)	1.02 (0.79–1.30)	MVA	5	No GAS: 2068(95%)	27.4%	McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5	No GAS: 24 (27%)	NA	Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																										
Zhang, 2017 [31]	66	≥200 mg PPI	GAS: 29 (23%)	52.2%	0.30 (0.09–0.99)	0.37 (0.11–1.23) *	UVA *, MVA	7																																																																																																																		
			No GAS: 96 (77%)	36.5%					Lalani, 2017 [16]	NA	≥1 dose PPI	GAS: 120 (5%)	23.3%	1.05 (0.77–1.44)	1.02 (0.79–1.30)	MVA	5	No GAS: 2068(95%)	27.4%	McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5	No GAS: 24 (27%)	NA	Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																					
Lalani, 2017 [16]	NA	≥1 dose PPI	GAS: 120 (5%)	23.3%	1.05 (0.77–1.44)	1.02 (0.79–1.30)	MVA	5																																																																																																																		
			No GAS: 2068(95%)	27.4%					McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5	No GAS: 24 (27%)	NA	Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																																
McAlister, 2018 [25]	NA	≥90 days	GAS: 66 (73%)	NA	0.99 (0.51–1.93)	1.25 (0.76–2.07)	MVA	5																																																																																																																		
			No GAS: 24 (27%)	NA					Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7	No GAS: 311,853 (88.3%)	NA	Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																																											
Tvingsholm, 2018 [28]	1.52 (0.50–3.89)	≥2 prescriptions within 6 months	GAS: 41,218 (11.7%)	NA	1.29 (1.27–1.31)	NA	MVA	7																																																																																																																		
			No GAS: 311,853 (88.3%)	NA					Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5	No GAS: 164 (76.6%)	NA	Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																																																						
Wong, 2019 [29]	NA	Any time PPI during capecitabine	GAS: 50 (23.4%)	NA	1.68 (0.75–3.80)	2.20 (1.14–4.25)	MVA	5																																																																																																																		
			No GAS: 164 (76.6%)	NA					Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7	No GAS: 969 (76%)	NA	Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																																																																	
Fang, 2019 [21]	NA	≥20	GAS: 309 (24%)	NA	1.67 (1.33–2.09)	0.99 (0.80–1.23)	MVA	7																																																																																																																		
			No GAS: 969 (76%)	NA					Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6	No GAS: 273 (82%)	NA	Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																																																																												
Mir, 2019 [17]	27.6 (22.9–35.4)	≥80	GAS: 59 (18%)	NA	1.81 (1.31–2.49)	1.49 (1.11–1.99)	MVA	6																																																																																																																		
			No GAS: 273 (82%)	NA					Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8	No GAS: 9695 (77.3%)	NA																																																																																																							
Sharma, 2019 [26]	NA	≥30 days within 3 months	GAS: 2843 (22.7%)	NA	1.10 (1.04–1.17)	NA	MVA	8																																																																																																																		
			No GAS: 9695 (77.3%)	NA																																																																																																																						

* When both univariate and multivariate analyses were performed, HR results of multivariate analyses are reported. Legend: CI, confidence interval; GAS, gastric acid suppressants; HR, hazard ratio; NA, not available; NA, not determined; NOS, Newcastle-Ottawa Scale; MVA, multivariate analysis; ORR, overall response rate; OS, overall survival; PFS, progression free survival; UVA, univariate analysis.

All studies were retrospective except for a pooled analysis of phase 2–3 studies by Lalani et al. [16] and a secondary analysis of a randomized prospective trial by Chu et al. [19]. Oncologic treatment consisted of oral TKIs in $n = 11$ studies, while in $n = 4$ studies patients received oral chemotherapy (i.e., capecitabine); one study did not include information regarding the type of study drugs. Oncologic diagnoses were cancers of the gastrointestinal tract (GI, $n = 5$ studies), RCC ($n = 3$ studies), NSCLC ($n = 5$ studies), and soft tissue sarcomas or mixed histologies solid tumors in $n = 3$ studies. Quality according to NOS scale was moderate (range 5–8; median 6).

2.1. Overall Survival and Progression-Free Survival with GAS vs. no GAS

$N = 15$ studies reported data on OS. Because the heterogeneity test showed a high level of heterogeneity ($I^2 = 68\%$, $p < 0.01$) among studies, a random effects model was used for the analysis. The OS of patients receiving concomitant GAS therapy was significantly worse (HR = 1.31, 95%CI: 1.20–1.43; $p < 0.01$; Figure 2) compared to those of patients not receiving GAS. Similarly, the use of GAS reduced PFS in $n = 13$ studies that reported data on PFS (HR = 1.3, 95%CI 1.07–1.57; $p < 0.007$; Figure 3). Heterogeneity was high ($I^2 = 74\%$), so a random effects model was used.




Figure 2. Forest plot for overall survival of the analyzed studies.




Figure 3. Forest plot for progression free survival of the analyzed studies.

2.2. Subgroup Analysis

In a separate analysis of studies involving patients treated with TKIs, the use of concomitant GAS was similarly associated with poorer OS (HR = 1.35, 95%CI 1.16–1.56; $p < 0.01$). Similarly, capecitabine assumption with GAS resulted in increased mortality (HR = 1.37, 95%CI 1.1–1.7; $p < 0.01$). We also searched for a distinct correlation of concomitant GAS in different tumor types: only studies of EGFR-mutated NSCLC patients receiving TKIs and either PPIs or H2RAs and those with GI cancers receiving all PPIs and oral chemotherapy retained a significant correlation between GAS and poor survival (HR = 1.47, 95%CI 1.27–1.71; $p < 0.01$ and HR = 1.3, 95%CI 1.02–1.66; $p = 0.04$), while in the case of renal cell carcinoma, the correlation between GAS assumption and reduced survival was missing. In patients with lung cancer on anti-EGFR, regression between H2RA and HR for OS was not significant, so the contribution of H2RA does not seem relevant for the final outcome.

In some studies, both PPIs and H2RAs were administered. After exclusion of these studies, $n = 7$ publications included only patients taking PPIs, and HR for OS was similar to the whole population (HR = 1.22, 95%CI 1.09–1.36; $p < 0.01$). In studies that reported median follow-up ($n = 6$), OS was still poorer in patients taking GAS (HR = 1.29, 95%CI 1.27–1.31; $p < 0.01$).

2.3. Overall Response Rate

In few studies with data available, PPIs did not influence ORR (OR = 0.89, 95%CI 0.53–1.47; $p = 0.64$, Figure 4).




Figure 4. Forest plot for overall response rate of the analyzed studies.

2.4. Publication Bias

A funnel plot was used to assess publication bias in the studies evaluating OS with concomitant GAS versus no GAS therapy in cancer patients. No publication bias was detected. Furthermore, Egger’s test was not significant ($p = 0.39$) (Figure 5).




Figure 5. Funnel plot for publication bias in overall survival analysis.

3. Discussion

This is the first meta-analysis exploring the role of concomitant GAS therapy during administration of oral anti-cancer agents for treatment of solid tumors. According to our results, GAS therapy seems to negatively impact on OS and PFS, while it has no impact on ORR.

GAS, and above all PPIs, are among the most commonly prescribed drugs worldwide. Their principal application is treatment of gastroesophageal inflammatory syndromes, such as gastroesophageal reflux disease, esophagitis, and peptic ulcer disease [32]. Given their mild toxicity profile, the use of PPIs has spread over the last 20 years, and we are now facing an overuse in patients with benign conditions or who do not need this specific therapy. Recently, various studies have related PPI use to increased incidence of respiratory tract and *Clostridium difficile* infections, mainly related to an altered commensal intestinal microbiome, as a consequence of raised gastric pH and bacterial overgrowth [33].

The clinical impact of concomitant use of GAS therapy and oral anti-cancer agents remains controversial. Numerous pharmacokinetic studies have addressed this question, showing a possible detrimental effect of GAS on oral anti-cancer drug absorption. However, this phenomenon varies according not only to the drugs analyzed, but depends also on specific drug–drug interactions differing among drugs of the same class [11,12,34,35]. As an example, Egorin et al. showed that PPIs may significantly decrease dasatinib plasmatic levels, while they do not impact on imatinib levels [34]. A similar effect was shown in a small series of patients using concomitant GAS and erlotinib [11], but was not confirmed by data of patients included in the BR.21 trial database [35]. This retrospective analysis on clinical outcomes of patients receiving concomitant GAS and erlotinib showed no differences in plasma drug levels and survival outcomes compared with patients who did not take concomitant GAS [35]. However, the pH-dependent absorption of erlotinib was confirmed in a randomized pharmacokinetic study, which demonstrated that concomitant Cola intake led to a clinically relevant increase in erlotinib bioavailability during esomeprazole treatment due to a temporarily lowered intragastric pH [36]. Analyses on the pharmacokinetics of different TKIs showed that afatinib is highly soluble throughout the physiologic pH range and may therefore have fewer interactions with GAS, compared with gefitinib or erlotinib [37]. A similar effect was observed for osimertinib, where plasmatic levels were not determined by food or PPI co-administration [12]. With our meta-analysis, we reported a significant correlation between GAS and poor survival only for the NSCLC and CRC subgroups, while there was no significant impact on survival when RCC series were considered. A possible explanation may be found in the difference between oral TKIs used in NSCLCs and RCCs. Indeed, TKIs used in lung cancer own anti-EGFR activity (gefitinib and erlotinib), while TKIs used in RCCs have mainly anti-vascular endothelial growth factor (VEGF) properties (sunitinib, sorafenib, axitinib and pazopanib). Moreover, our results are consistent with findings of a previous pooled analysis of metastatic RCC patients treated in phase II and III trials. Indeed, OS results were similar between PPI and non-PPI users in the case of anti-VEGF TKI use [16].

There are two main concerns related to alterations in pharmacokinetics during concomitant GAS therapy. The first is that combined use of PPIs and TKIs may increase the treatment-related adverse events (AEs) of both drugs. Although intuitive, this mechanism is also controversial: in a recent report from Cho et al., concomitant GAS therapy increased gefitinib-induced hepatotoxicity [38]. However, another case series of patients treated with gefitinib and erlotinib did not show differences in the incidence of cutaneous AEs and diarrhea, when comparing patients receiving concomitant GAS to those who did not [30]. Similar reports of patients undergoing concomitant capecitabine and PPIs showed that rates of treatment discontinuation and/or dose reduction due to toxicities were comparable to that of patients not receiving GAS therapy [20,29].

The second important issue lies in the potentially reduced absorption and subsequent compromised anti-cancer drug effect. Reports from the literature on this topic mainly consist of case series, reporting heterogeneous data in terms of patient populations, anti-cancer drugs (chemotherapy, TKIs), GAS therapy (PPIs, H2RA, or both), and outcomes (survival vs response vs AEs incidence). Our meta-analysis

confirmed that concomitant GAS can have a negative impact on PFS and OS, however without significant effects on ORR. One of the possible reasons for the worse survival outcomes is that patients requiring GAS are older and have various comorbidities (e.g., cardiovascular disease requiring aspirin and therefore PPI therapy). Another theory is that concomitant GAS therapy reduces serum levels of anti-cancer drugs under the therapeutic threshold, thus increasing the risk for distant metastasis and disease progression. Although previous studies show that TKIs are effective even at low serum levels, it is recognized that the cerebrospinal fluid penetration rate of first-generation TKIs is only around 2% [39]. Thus, the concomitant use of drugs reducing gastric absorption of TKIs may further reduce their serum levels to an insufficient plasmatic concentration [40].

Given these two considerations, we can speculate that concomitant administration of GAS drugs during anti-cancer therapy does not significantly affect ORR because of the maintenance of an adequate therapeutic anti-cancer threshold. On the contrary, over a long period, GAS administration might affect therapeutic activity of anti-cancer drugs. This element, combined with risk factors of age and comorbidities of patients treated with GAS, might explain the worsened survival rates for this subgroup of patients. The relatively low number of studies reporting complete OS results (6 out of 16 analyzed studies), however, makes the interpretation of this result even more speculative. The observations of our analysis are only hypotheses-generating: data available so far can be used as starting points to carry on further prospective parallel data collection and analyses in clinical practice.

Our meta-analysis has some intrinsic limitations. First of all, patients taking PPIs may have an intrinsically poor performance status and/or chronic conditions that require continuous GAS. Secondly, use of PPIs was not offered with a randomized design so that patients treated with PPIs may have suffered from concomitant gastritis/dyspepsia and/or may have taken steroids for supportive care, consequently needing chronic GAS therapy. Thirdly, there is uncertainty regarding the correct administration of PPIs right before antitumoral treatment.

Moreover, PPIs and H2RAs have different mechanisms of action and potency. Due to the heterogeneity of studies analyzed, we only have the results of a subgroup analysis of studies analyzing the effect of single GAS therapy (i.e., PPIs or H2RAs), with only limited data on length of overlapping therapies.

Finally, other pharmacological interactions (e.g., with the CYP3A4 citochrome) may have reduced plasmatic concentration of anti-EGFR agents.

4. Materials and Methods

This study followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group guidelines and checklist [41] (Figure 1, Table 3).

Table 3. MOOSE Checklist for Meta-analyses of Observational Studies.

Item No	Recommendation	Reported on Page No
Reporting of background should include		
1	Problem definition	1,2
2	Hypothesis statement	1,2
3	Description of study outcome(s)	11
4	Type of exposure or intervention used	11
5	Type of study designs used	11
6	Study population	11
Reporting of search strategy should include		
7	Qualifications of searchers (e.g., librarians and investigators)	1

Table 3. Cont.

Item No	Recommendation	Reported on Page No
8	Search strategy, including time period included in the synthesis and key words	11
9	Effort to include all available studies, including contact with authors	11
10	Databases and registries searched	11
11	Search software used, name and version, including special features used (e.g., explosion)	11
12	Use of hand searching (e.g., reference lists of obtained articles)	11, Figure 1
13	List of citations located and those excluded, including justification	11, Figure 1
14	Method of addressing articles published in languages other than English	11
15	Method of handling abstracts and unpublished studies	11
16	Description of any contact with authors	11
Reporting of methods should include		
17	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	11
18	Rationale for the selection and coding of data (e.g., sound clinical principles or convenience)	11
19	Documentation of how data were classified and coded (e.g., multiple raters, blinding and interrater reliability)	11
20	Assessment of confounding (e.g., comparability of cases and controls in studies where appropriate)	11
21	Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results	11
22	Assessment of heterogeneity	7,8, Figure 5
23	Description of statistical methods (e.g., complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	12
24	Provision of appropriate tables and graphics	Figure 1
Reporting of results should include		
25	Graphic summarizing individual study estimates and overall estimate	Tables 1 and 2
26	Table giving descriptive information for each study included	Tables 1 and 2
27	Results of sensitivity testing (e.g., subgroup analysis)	2, 6–8, Figures 2–4
28	Indication of statistical uncertainty of findings	7,8, Figure 5
29	Quantitative assessment of bias (e.g., publication bias)	7,8, Figure 5
30	Justification for exclusion (e.g., exclusion of non-English language citations)	Figure 1, 11
31	Assessment of quality of included studies	11
Reporting of conclusions should include		
32	Consideration of alternative explanations for observed results	8,9
33	Generalization of the conclusions (i.e., appropriate for the data presented and within the domain of the literature review)	12
34	Guidelines for future research	8,9,11
35	Disclosure of funding source	12

4.1. Data Extraction and Quality Assessment

A protocol was defined prior to the search including the population criteria, description of oncologic treatments, comparisons, and outcomes of interest. A systematic literature search was performed using PubMed (MEDLINE), EMBASE and The Cochrane Library. The search was performed comprehensively using several databases from each one's earliest start until 1st August 2019. We sought to identify all English language research evaluating the effect of GAS use on the outcomes of patients receiving concomitant oral chemotherapy or TKIs for solid tumors. For the process of evidence acquisition, the literature was queried using the following terms [MeSH]: "gastric acid suppressant" OR "proton pump inhibitors", and "chemotherapy" or "tyrosine kinase inhibitors" AND "carcinoma" or "cancer" AND "survival". References of included studies were hand-searched in order to identify potentially relevant adjunctive papers. For each study we extracted the following information, if available: number of patients, baseline patient characteristics, data regarding oncologic treatments, progression-free (PFS) or recurrence-free (RFS) survivals and overall survival (OS) or the corresponding HRs, and overall response rates (ORRs) in the 2 arms.

Two independent reviewers (AI and FP) evaluated all studies in order to verify the inclusion criteria. Study selection was conducted with a two-phase screening. First level screening excluded titles and abstracts meeting the following criteria: (a) case reports, letters, comments, and reviews not reporting original data; (b) in vivo and/or in vitro studies; (c) studies involving fewer than 10 patients; and (d) language publication other than English. Studies matching inclusion criteria were obtained in the complete form and reviewed in their full-text version for an advanced assessment. Second level full-text screening was performed in order to include studies with the following criteria: (1) studies involving patients with solid tumors receiving oral chemotherapy or TKIs; (2) studies reporting outcomes of patients receiving concomitant GAS therapy compared to those who did not; (3) information regarding HRs or survival curves for OS and/or PFS and/or ORRs for patients using GAS compared to those who did not. Differences of opinion were resolved by agreement between the reviewers. Study quality was independently evaluated using the Newcastle-Ottawa Quality Assessment scale for case-control studies [42]. Disagreement was also resolved by consultation and consensus.

4.2. Statistical Analysis

The primary outcome of interest was OS. The secondary endpoints were PFS and ORR. The HRs and 95% CIs from each study were either extracted directly from original papers or calculated using Kaplan–Meier curves based on the method of Tierney et al [43]. Random effects models with inverse variance weighting were calculated using Review Manager (RevMan 5.3, The Nordic Cochrane Center, Copenhagen, Denmark). The heterogeneity of the underlying population was assessed using the Q-statistic and I^2 test. For the interpretation, I^2 values greater than 50% were considered to be heterogeneous [44]. Publication bias was assessed by visually evaluating a funnel plot (Begg's and Egger's test, Figure 4).

5. Conclusions

The use of GAS during cancer therapy with capecitabine or TKIs should be offered with caution because it may result in a reduction of anti-cancer treatment and may significantly affect therapeutic outcomes. In our meta-analysis, we observed a significantly worse OS and PFS in patients receiving GAS during cancer treatment with anti-EGFR TKIs or capecitabine-based regimens in GI cancers and NSCLC. In conclusion, except for clear clinical reasons (concomitant use of steroids/non-steroidal anti-inflammatory drugs, severe gastroesophageal reflux disease/gastritis/peptic ulcer) GAS should be avoided during treatment with oral anti-cancer drugs for solid tumors.

Author Contributions: Conceptualization, A.I., M.G. and F.P.; Methodology, F.P.; Software, F.P.; Validation, F.P.; Formal Analysis, F.P.; Investigation, F.P.; Resources, M.G. and F.G.; Data Curation, F.P.; Writing—Original Draft

Preparation, A.I., M.G., F.P. and A.F.; Writing—Review & Editing, G.T., F.G. and E.R.; Visualization, F.P. and A.I.; Supervision, F.G. and A.F.; Project Administration, F.P.; Funding Acquisition, F.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kaye, S.B. New antimetabolites in cancer chemotherapy and their clinical impact. *Br. J. Cancer* **1998**, *78* (Suppl. 3), 1–7. [[CrossRef](#)]
2. Marty, M.; Extra, J.M.; Espie, M.; Leandri, S.; Besenval, M.; Krikorian, A. Advances in vinca-alkaloids: Navelbine. *Nouv Rev. Fr. d'Hematol.* **1989**, *31*, 77–84.
3. O'Reilly, S.M.; Newlands, E.S.; Glaser, M.G.; Brampton, M.; Rice-Edwards, J.M.; Illingworth, R.D.; Richards, P.G.; Kennard, C.; Colquhoun, I.R.; Lewis, P.; et al. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. *Eur. J. Cancer* **1993**, *29A*, 940–942. [[CrossRef](#)]
4. Hutson, T.E.; Lesovoy, V.; Al-Shukri, S.; Stus, V.P.; Lipatov, O.N.; Bair, A.H.; Rosbrook, B.; Chen, C.; Kim, S.; Vogelzang, N.J. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised open-label phase 3 trial. *Lancet Oncol.* **2013**, *14*, 1287–1294. [[CrossRef](#)]
5. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N. Engl. J. Med.* **2010**, *362*, 2380–2388. [[CrossRef](#)]
6. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N. Engl. J. Med.* **2007**, *356*, 115–124. [[CrossRef](#)]
7. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* **2012**, *13*, 239–246. [[CrossRef](#)]
8. Sternberg, C.N.; Davis, I.D.; Mardiak, J.; Szczylik, C.; Lee, E.; Wagstaff, J.; Barrios, C.H.; Salman, P.; Gladkov, O.A.; Kavina, A.; et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. *J. Clin. Oncol.* **2010**, *28*, 1061–1068. [[CrossRef](#)]
9. Van der Graaf, W.T.; Blay, J.Y.; Chawla, S.P.; Kim, D.W.; Bui-Nguyen, B.; Casali, P.G.; Schoffski, P.; Aglietta, M.; Staddon, A.P.; Beppu, Y.; et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* **2012**, *379*, 1879–1886. [[CrossRef](#)]
10. Savarino, V.; Dulbecco, P.; De Bortoli, N.; Ottonello, A.; Savarino, E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. *Eur. J. Intern. Med.* **2017**, *37*, 19–24. [[CrossRef](#)]
11. Ohgami, M.; Kaburagi, T.; Kurosawa, A.; Doki, K.; Shiozawa, T.; Hizawa, N.; Homma, M. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. *Ther. Drug Monit.* **2018**, *40*, 699–704. [[CrossRef](#)] [[PubMed](#)]
12. Vishwanathan, K.; Dickinson, P.A.; Bui, K.; Cassier, P.A.; Greystoke, A.; Lisbon, E.; Moreno, V.; So, K.; Thomas, K.; Weilert, D.; et al. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. *J. Clin. Pharmacol.* **2018**, *58*, 474–484. [[CrossRef](#)] [[PubMed](#)]
13. Budha, N.R.; Frymoyer, A.; Smelick, G.S.; Jin, J.Y.; Yago, M.R.; Dresser, M.J.; Holden, S.N.; Benet, L.Z.; Ware, J.A. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy? *Clin. Pharmacol. Ther.* **2012**, *92*, 203–213. [[CrossRef](#)] [[PubMed](#)]
14. Suttle, A.B.; Ball, H.A.; Molimard, M.; Hutson, T.E.; Carpenter, C.; Rajagopalan, D.; Lin, Y.; Swann, S.; Amado, R.; Pandite, L. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. *Br. J. Cancer* **2014**, *111*, 1909–1916. [[CrossRef](#)]

15. Verheijen, R.B.; Swart, L.E.; Beijnen, J.H.; Schellens, J.H.M.; Huitema, A.D.R.; Steeghs, N. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: Opportunities for dose optimization. *Cancer Chemother. Pharmacol.* **2017**, *80*, 1171–1178. [[CrossRef](#)]
16. Lalani, A.A.; McKay, R.R.; Lin, X.; Simantov, R.; Kaymakalan, M.D.; Choueiri, T.K. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. *Clin. Genitourin. Cancer* **2017**, *15*, 724–732. [[CrossRef](#)]
17. Mir, O.; Touati, N.; Lia, M.; Litiere, S.; Le Cesne, A.; Sleijfer, S.; Blay, J.Y.; Leahy, M.; Young, R.; Mathijssen, R.H.J.; et al. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. *Clin. Cancer Res.* **2019**, *25*, 1479–1485. [[CrossRef](#)]
18. Chen, Y.M.; Lai, C.H.; Chang, H.C.; Chao, T.Y.; Tseng, C.C.; Fang, W.F.; Wang, C.C.; Chung, Y.H.; Wang, Y.H.; Su, M.C.; et al. Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *PLoS ONE* **2016**, *11*, e0149722. [[CrossRef](#)]
19. Chu, M.P.; Ghosh, S.; Chambers, C.R.; Basappa, N.; Butts, C.A.; Chu, Q.; Fenton, D.; Joy, A.A.; Sangha, R.; Smylie, M.; et al. Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. *Clin. Lung Cancer* **2015**, *16*, 33–39. [[CrossRef](#)]
20. Chu, M.P.; Hecht, J.R.; Slamon, D.; Wainberg, Z.A.; Bang, Y.J.; Hoff, P.M.; Sobrero, A.; Qin, S.; Afenjar, K.; Houe, V.; et al. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. *JAMA Oncol.* **2017**, *3*, 767–773. [[CrossRef](#)]
21. Fang, Y.H.; Yang, Y.H.; Hsieh, M.J.; Hung, M.S.; Lin, Y.C. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment—A nationwide population-based study. *Cancer Manag Res.* **2019**, *11*, 8539–8546. [[CrossRef](#)] [[PubMed](#)]
22. Graham, C.; Orr, C.; Bricks, C.S.; Hopman, W.M.; Hammad, N.; Ramjeesingh, R. A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival. *Curr. Oncol.* **2016**, *23*, e583–e588. [[CrossRef](#)] [[PubMed](#)]
23. Ha, V.H.; Ngo, M.; Chu, M.P.; Ghosh, S.; Sawyer, M.B.; Chambers, C.R. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? *J. Oncol. Pharm. Pract.* **2015**, *21*, 194–200. [[CrossRef](#)] [[PubMed](#)]
24. Kumarakulasinghe, N.B.; Syn, N.; Soon, Y.Y.; Asmat, A.; Zheng, H.; Loy, E.Y.; Pang, B.; Soo, R.A. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction. *Oncotarget* **2016**, *7*, 85542–85550. [[CrossRef](#)]
25. McAlister, R.K.; Aston, J.; Pollack, M.; Du, L.; Koyama, T.; Chism, D.D. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma. *Oncologist* **2018**, *23*, 686–692. [[CrossRef](#)]
26. Sharma, M.; Holmes, H.M.; Mehta, H.B.; Chen, H.; Aparasu, R.R.; Shih, Y.T.; Giordano, S.H.; Johnson, M.L. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. *Cancer* **2019**, *125*, 1155–1162. [[CrossRef](#)]
27. Sun, J.; Ilich, A.I.; Kim, C.A.; Chu, M.P.; Wong, G.G.; Ghosh, S.; Danilak, M.; Mulder, K.E.; Spratlin, J.L.; Chambers, C.R.; et al. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients. *Clin. Colorectal. Cancer* **2016**, *15*, 257–263. [[CrossRef](#)]
28. Tvingsholm, S.A.; Dehlendorff, C.; Osterlind, K.; Friis, S.; Jaattela, M. Proton pump inhibitor use and cancer mortality. *Int. J. Cancer* **2018**, *143*, 1315–1326. [[CrossRef](#)]
29. Wong, G.G.; Ha, V.; Chu, M.P.; Dersch-Mills, D.; Ghosh, S.; Chambers, C.R.; Sawyer, M.B. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. *Clin. Colorectal. Cancer* **2019**, *18*, 72–79. [[CrossRef](#)]
30. Zenke, Y.; Yoh, K.; Matsumoto, S.; Umemura, S.; Niho, S.; Ohmatsu, H.; Goto, K.; Ohe, Y. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. *Clin. Lung Cancer* **2016**, *17*, 412–418. [[CrossRef](#)]

31. Zhang, J.L.; Liu, M.; Yang, Q.; Lin, S.Y.; Shan, H.B.; Wang, H.Y.; Xu, G.L. Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. *World J. Gastroenterol.* **2017**, *23*, 2575–2584. [[CrossRef](#)]
32. Targownik, L.E.; Metge, C.; Roos, L.; Leung, S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. *Am. J. Gastroenterol.* **2007**, *102*, 942–950. [[CrossRef](#)] [[PubMed](#)]
33. Corleto, V.D.; Festa, S.; Di Giulio, E.; Annibale, B. Proton pump inhibitor therapy and potential long-term harm. *Curr. Opin. Endocrinol. Diabetes Obes.* **2014**, *21*, 3–8. [[CrossRef](#)] [[PubMed](#)]
34. Egorin, M.J.; Shah, D.D.; Christner, S.M.; Yerk, M.A.; Komazec, K.A.; Appleman, L.R.; Redner, R.L.; Miller, B.M.; Beumer, J.H. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. *Br. J. Clin. Pharmacol.* **2009**, *68*, 370–374. [[CrossRef](#)] [[PubMed](#)]
35. Hilton, J.F.; Tu, D.; Seymour, L.; Shepherd, F.A.; Bradbury, P.A. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. *Lung Cancer* **2013**, *82*, 136–142. [[CrossRef](#)] [[PubMed](#)]
36. Van Leeuwen, R.W.; Peric, R.; Hussaarts, K.G.; Kienhuis, E.; NS, I.J.; De Bruijn, P.; Van der Leest, C.; Codrington, H.; Kloover, J.S.; Van der Holt, B.; et al. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer. *J. Clin. Oncol.* **2016**, *34*, 1309–1314. [[CrossRef](#)]
37. Xu, Z.Y.; Li, J.L. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. *Onco Targets Ther.* **2019**, *12*, 5467–5484. [[CrossRef](#)]
38. Cho, S.; Yee, J.; Kim, J.Y.; Jeong Rhie, S.; Gwak, H.S. Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity. *J. Clin. Pharmacol.* **2018**, *58*, 263–268. [[CrossRef](#)]
39. Togashi, Y.; Masago, K.; Masuda, S.; Mizuno, T.; Fukudo, M.; Ikemi, Y.; Sakamori, Y.; Nagai, H.; Kim, Y.H.; Katsura, T.; et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. *Cancer Chemother. Pharmacol.* **2012**, *70*, 399–405. [[CrossRef](#)]
40. Deng, Y.; Feng, W.; Wu, J.; Chen, Z.; Tang, Y.; Zhang, H.; Liang, J.; Xian, H.; Zhang, S. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. *Mol. Clin. Oncol.* **2014**, *2*, 116–120. [[CrossRef](#)]
41. Stroup, D.F.; Berlin, J.A.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.; Thacker, S.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. *Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.* *JAMA* **2000**, *283*, 2008–2012. [[CrossRef](#)] [[PubMed](#)]
42. Wells, G.; Shea, B.; O’Connell, D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. *Eur. J. Epidemiol.* **2015**, *25*, 603–605.
43. Parmar, M.K.; Torri, V.; Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat. Med.* **1998**, *17*, 2815–2834. [[CrossRef](#)]
44. Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **2002**, *21*, 1539–1558. [[CrossRef](#)] [[PubMed](#)]

